Puma Biotechnology | PBYI - Stock


Puma Biotechnology reported $9.48M in Stock for its fiscal quarter ending in September of 2025.





Stock Change Date
Agios Pharmaceuticals USD 32.92M 886K Dec/2025
Alnylam Pharmaceuticals USD 82.72M 7.34M Dec/2025
Amgen USD 6.22B 121M Dec/2025
Biogen USD 2.17B 41.3M Dec/2025
BioMarin Pharmaceutical USD 1.3B 83.29M Dec/2025
Daiichi Sankyo JPY 608.55B 93.64B Sep/2025
Esperion Therapeutics USD 108.54M 5.93M Sep/2025
Exelixis USD 27.4M 3.92M Sep/2025
Gilead Sciences USD 1.78B 40M Sep/2025
Glaxosmithkline GBP 6.12B 46M Sep/2025
Incyte USD 101.06M 17.61M Dec/2025
MacroGenics USD 8.75M 530K Sep/2025
Moderna USD 332M 92M Sep/2025
Novartis USD 6.42B 114M Sep/2025
Pfizer USD 11.47B 201M Sep/2025
PTC Therapeutics USD 79.65M 26.96M Dec/2025
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 3.2B 53.6M Dec/2025
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 914.74M 162.42M Dec/2025
Takeda JPY 1.41T 107.71B Dec/2025
TG Therapeutics USD 125.59M 21.37M Dec/2025
Ultragenyx Pharmaceutical USD 52.2M 5.7M Sep/2025
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025
Vertex Pharmaceuticals USD 1.69B 60M Dec/2025